BrainStorm Cell Therapeutics Inc.
http://www.brainstorm-cell.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BrainStorm Cell Therapeutics Inc.
BrainStorm's Cell Therapy Disappoints In Phase III ALS Study
Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.
Right To Try Conversation Should Be Redirected Toward Reimbursement Of Unapproved Drugs, Experts Say
King & Spalding Partner David Farber called for amending Medicare and Medicaid statutes so that unapproved treatments can be reimbursed for terminally ill patients who have exhausted all other options.
Unlicensed Stem Cell Clinics Are 'Surrogate' For Right To Try, US FDA's Marks Says
CBER director said unlicensed stem cell clinics often report adverse events not made public, which is a concern under Right To Try.
ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET